NEW GERMANY FUND INC (GF) Stock News

Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.

argenx presented new clinical data at the AANEM and MGFA scientific sessions demonstrating deepening improvements in ocular myasthenia gravis (MG) with VYVGART, sustained one-year efficacy in anti-AChR antibody-negative MG patients, and benefits of earlier treatment initiation. Real-world evidence from over 1,100 U.S. MG patients showed greater clinical gains when treatment started within one year of diagnosis. Long-term CIDP data reinforced consistent safety and efficacy, with a Phase 4 study supporting direct transition from IVIg. Pipeline candidates empasiprubart and adimanebart showed promising Phase 2 results in multifocal motor neuropathy and congenital myasthenic syndrome respectively.

HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.

HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.

Elevar Therapeutics announced FDA approval of Lyrfigtu (lirafugratinib) for treating cholangiocarcinoma patients with FGFR2 fusion or rearrangement. The drug demonstrated a 46% objective response rate and 11.8-month median duration of response in the Phase 1/2 ReFocus trial. Lyrfigtu is expected to be available in the U.S. by Q4 2026 and represents a second-line treatment option for this rare bile duct cancer.

GlobalFoundries (GFS) has partnered with SMART Photonics to combine silicon and indium phosphide photonics manufacturing capabilities. The company reported 62% year-over-year revenue growth in communications infrastructure and data center in Q2 2026, driven by strong AI and optical networking demand. GFS is advancing 1.6-terabit and 3.2-terabit optical modules while producing 200-gigabit-per-lane technology, though financial contributions from the SMART partnership will take time to materialize.

GlobalFoundries has signed a multi-year agreement with Marvell Technology to expand silicon germanium (SiGe) production capacity at its Burlington, Vermont facility. The expansion will support next-generation optical transceivers and networking solutions for AI and cloud data centers. GFS shares have outperformed the industry over the past year, though the company faces competition from UMC and TSMC in the optical connectivity market.

GlobalFoundries is expanding its semiconductor partnerships across AI, optical networking, automotive, and quantum technologies. Recent deals include a long-term manufacturing agreement with Monolithic Power Systems and $375 million in R&D funding from the U.S. Department of Commerce for quantum semiconductors. The company also partnered with RAAAM Memory Technologies on power-efficient memory solutions. However, GFS stock has underperformed the industry by 33.6% over the past year and trades at a higher valuation than peers, with a Zacks Rank #3 (Hold) rating.

The iShares Emerging Markets Equity Factor ETF (EMGF) is a smart beta ETF launched in 2015 with $1.94 billion in assets under management. It offers a low expense ratio of 0.26% and has delivered strong performance with 26.35% gains year-to-date and 37.91% over the past year. However, the article suggests investors consider cheaper alternatives like VWO (0.06% expense ratio) and IEMG (0.09% expense ratio) for lower-cost, lower-risk exposure to emerging markets.

HUTCHMED announced positive Phase III SANOVO trial results showing that ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) demonstrated statistically significant progression-free survival improvements and encouraging overall survival benefits in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China, extending the clinical value of the combination into the first-line setting.

HUTCHMED received conditional approval from China's NMPA for ATLED® (fanregratinib), a selective FGFR 1/2/3 inhibitor, for treating advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements in previously treated patients. The Phase II trial demonstrated an objective response rate of 42.5%, median PFS of 6.9 months, and median OS of 16.6 months, addressing a significant therapeutic gap in this aggressive cancer type.

Enigmatig Limited (NYSE American: EGG), a global business enabler, announced its investment in KUNGFULAND, a Singapore-Canada co-production action-comedy film that began principal photography in June 2026. The film, set in 1999 Chinatown and paying homage to 1970s martial arts cinema, utilizes advanced LED wall virtual production technology and features an international cast including David Chiang. The project is produced by Singapore's Ajacent Media and Canada's 100 Dragons with support from Singapore's IMDA.

Enigmatig Limited (NYSE American: EGG), a global business enabler platform, announced its investment in 'KUNGFULAND,' a Singapore-Canada co-produced action-comedy film set in 1999 Chinatown. The film, which began principal photography in June 2026, is the first feature-length scripted co-production between the two countries utilizing virtual production technology and LED wall technology. The project is co-produced by Singapore's Ajacent Media and Canada's 100 Dragons, with support from Singapore's IMDA.

Enigmatig Limited (NYSE American: EGG), a global business enabler, announced an investment in KUNGFULAND, a Singapore-Canada co-produced action-comedy film shot using virtual production technology. The film, set in 1999 Chinatown and inspired by 1970s kung fu cinema, features international cast members and Hong Kong legend David Chiang. It represents Enigmatig's commitment to supporting creative talent and local stories reaching global audiences.

Enigmatig Limited announced its investment in KUNGFULAND, a Singapore-Canada co-production action-comedy film set in 1999 Chinatown. The film marks the first scripted feature-length production between the two countries using virtual production technology, with principal photography beginning June 10, 2026 at AUX Infinite Studios in Singapore. The project is produced by Ajacent Media and 100 Dragons with support from Singapore's IMDA.

Enigmatig Limited (NYSE American: EGG) announced its investment in KUNGFULAND, a Singapore-Canada co-production action-comedy film that began principal photography in June 2026. The film, set in 1999 Chinatown, features virtual production technology and is being distributed by Shaw Organisation, Raven Banner Releasing, and Flourishing Films.

Enigmatig Limited announced its investment in KUNGFULAND, a Singapore-Canada co-produced action-comedy film shot using virtual production technology at AUX Infinite Studios. The film, set in 1999 Chinatown and inspired by 1970s martial arts cinema, stars Idrissa Sanogo Bamba, Ellen Wong, Dion Johnstone, and Hugh Tran with a cameo by David Chiang. The investment reflects Enigmatig's commitment to supporting creative talent and storytelling from Singapore reaching global audiences.

BioNTech and Bristol Myers Squibb announced interim results from the ROSETTA Lung-02 Phase 2/3 study showing that their bispecific PD-L1xVEGF-A immunomodulator candidate Pumitamig demonstrated encouraging anti-tumor activity in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The drug showed confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous NSCLC subtypes at the lower dose, with consistent efficacy across all PD-L1 expression levels. The companies are advancing a comprehensive global Phase 3 development program with multiple ongoing trials.

BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial showing that their investigational bispecific immunomodulator pumitamig combined with chemotherapy demonstrated encouraging anti-tumor activity in first-line non-small cell lung cancer, with confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous subtypes at the lower dose. The drug showed consistent efficacy across PD-L1 expression levels with a manageable safety profile, and is advancing through a comprehensive Phase 3 development program.